We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Biosearch Technologies Introduces Influenza A Subtyping ValuPanel™ Reagents

Read time: 1 minute

The influenza ValuPanel Reagents include the previously announced signatures for H1N1 viral strains, as well as a novel set associated with Influenza A subtypes.  The influenza ValuPanel assays were developed by the Centers for Disease Control and Prevention (CDC) and are sold under license from the CDC and F. Hoffmann-La Roche.

The Influenza A Subtyping ValuPanel Reagents comprise oligos based on the following seven signature sequences: universal strain of influenza A; influenza A H1 subtype; influenza A H3 subtype; influenza A H5a subtype; influenza A H5b subtype; universal strain of influenza B, and RNase P as a positive control.  Biosearch offers 2009 H1N1 and Influenza A Subtyping ValuPanel Reagents for Research Use Only (RUO) and both panels are available online at www.biosearchtech.com/products/valupanel-reagents.aspx for immediate purchase.

Ron Cook, President and CEO of Biosearch Technologies, comments, “Over the past few years, Biosearch has developed advanced manufacturing capability and quality system management which set us apart from traditional oligonucleotide suppliers. We are pleased to apply our expertise to provide these important new reagents for the detection of all major strains of influenza.  We expect to augment this listing as new assays become available.”

Biosearch Technologies is the leading provider of high value oligonucleotide components to manufacturers of molecular diagnostics and assays to screen for pathogens.  The company has a proven track record as a first responder to pandemics and was the original company to offer oligonucleotide probes and primers comprising the 2009 H1N1 detection panel developed and disclosed by the CDC.  FAM-BHQ® probes were key components in the “Swine Influenza Virus Real-time RT-PCR Detection Panel” designed by the CDC and continue to play the same essential role in the Influenza A Subtyping ValuPanel Reagents.  As the inventor and patent holder of the BHQ® (Black Hole Quencher®) technology, Biosearch offers worldwide access to these dyes as integral components to a broad range of genomic research applications.